**Question:** Best test for subacute cutaneous lupus erythematosus is

A. Anti-Ro/SSA antibodies
B. Direct Coombs test
C. Skin biopsy
D. Serum protein electrophoresis

**Correct Answer:** C. Skin biopsy

**Core Concept:** Subacute cutaneous lupus erythematosus (SCLE) is a subtype of systemic lupus erythematosus (SLE), an autoimmune disorder characterized by inflammation and damage to various tissues and organs. The autoimmune response in SLE is directed against nuclear antigens, such as anti-Ro/SSA antibodies which are found in up to 80% of patients with SCLE.

**Why the Correct Answer is Right:** Skin biopsy is the most appropriate test for diagnosing SCLE as it directly examines the skin lesions for characteristic histopathological features like perivascular lymphocytic infiltration, necrotizing vasculitis, and epidermal atrophy. These findings help in distinguishing SCLE from other cutaneous diseases with similar presentations.

**Why Each Wrong Option is Incorrect:**

A. Anti-Ro/SSA antibodies: While these antibodies are commonly found in patients with SCLE, a positive result alone is not sufficient for diagnosis. Skin biopsy is crucial for confirming the clinical suspicion of SCLE and distinguishing it from other autoimmune skin diseases.

B. Direct Coombs test: This test is used to detect the presence of anti-erythrocyte antibodies in patients with hemolytic anemia. It has no relevance to diagnosing SCLE or any autoimmune skin disorder.

D. Serum protein electrophoresis: This test is used to analyze serum proteins and is not relevant for diagnosing SCLE or assessing its severity. Skin biopsy remains the gold standard for confirming the diagnosis and ruling out other dermatological conditions.

**Clinical Pearl:** SCLE is a subtype of SLE that affects the skin, often exhibiting photosensitive rashes and mucosal ulcerations. Involvement of other organs, such as kidneys, lungs, or joints, could indicate a more severe form of SLE. Early recognition and diagnosis of SCLE are essential for proper management and avoiding unnecessary treatment with immunosuppressive drugs for autoimmune diseases without SCLE.